POST Online Media Lite Edition


Agios adds Maykin Ho to its board of directors

Staff writer |
Cambridge, Mass., USA - June 25, 2015, Cambridge, Mass., USA - Agios Pharmaceuticals, Inc., a pharmaceutical company, appointed Maykin Ho, former partner at the Goldman Sachs Group, as an independent director to the board.

Dr. Ho has more than 30 years of experience in the healthcare and finance industries. She is a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst, co-head of healthcare for global investment research and advisory director for healthcare investment banking.

Previously, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company. She is a member of the board of directors and chair of the audit committee for the Aaron Diamond AIDS Research Center in New York. She also served on the investment committee of the Society of Neuroscience.

Dr. Ho was a postdoctoral fellow in the pathology department of Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. She received a Ph.D. in microbiology and immunology and a B.S. from the State University of New York, Downstate Medical Center.

The board also made additional changes among its existing members. Kevin Starr, co-founder and partner at Third Rock Ventures, who has served as the company's chairman, chose not to stand for re-election when his term expired at the 2015 annual meeting of stockholders on June 23, 2015.

LATEST 5 MOVES FROM Massachusetts 

What to read next

Agios Pharma names Ian Clark to board of directors
Blueprint Medicines elects David Schenkein to the board
Agios Pharmaceuticals: David Schenkein CEO, Duncan Higgons COO